The effects of chemotherapy on the Wistar-Furth Wilms' Tumor.
An evaluation of single versus multiple therapy utilizing actinomycin D and vincristine to establish optimum therapeutic value on Wilms' tumor was completed in the present study. A Wistar/Furth Wilms' tumor model was treated with four dosage levels of actinomycin D and vincristine in single and multiple courses of treatment immediately after tumor injection. The results observed and analyzed indicated an optimum dose level for each drug and its most effective therapy course. Actinomycin D (at 300 mg/kg) in single or multiple dose was most effective, to an equal degree, in prolonging survival, decreasing the number of metastases, and the weight of the renal primary as well. Vincristine chemotherapy on a low-dose basis was associated chiefly with increased survival only.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003609:Dactinomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D011920:Rats, Inbred WF; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*; D009396:Wilms Tumor / Q000188:drug therapy* / Q000401:mortality
D003609:Dactinomycin; D014750:Vincristine